A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer.

Federica Miglietta Moira Ragazzi Bethania Fernades Gaia Griguolo Davide Massa Fabio Girardi Michele Bottosso Alessandra Bisagni Giovanni Zarrilli Francesca Porra Daniela Iannaccone Leocadia Dore Mariangela Gaudio Giacomo Santandrea Angelo Paolo Dei Tos Marcello Lo Mele Rita De Sanctis Alberto Zambelli Giancarlo Bisagni Valentina Guarneri Maria Vittoria Dieci

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

We have reported an independent prognostic impact of RD-TILs after anti-HER2+CT NAT, which might underlie an imbalance of the RD microenvironment towards immunosuppressive features. We provided a new composite prognostic score based on RCB+TIL, which was significantly associated with OS and proved to be more informative than the isolated evaluation of RCB and RD-TILs.

Keyphrases